These insights not only elucidate cardiovascular disease mechanisms but also highlight potential GEF‐targeted therapies (e.g., against VAV3, ARHGEF1, TIAM1, or PDZ‐RhoGEF) for hypertension, atherosclerosis, and myocardial regeneration. Here, ARHGEF2 is linked to cardiovascular disorder.